INHALD was created in September of 2013 to investigate and define cellular and molecular events underlying the pathogenesis of HIV-associated lung diseases (e.g., COPD and pulmonary hypertension). Effective antiretroviral therapy regimens (ART) have resulted in long-term survival of HIV-infected individuals and a rapidly expanding aging HIV-infected population. Infectious HIV-associated lung diseases, e.g., pneumonias and TB, and noninfectious HIV-related lung diseases, e.g., COPD and lung cancer, are much more prevalent in older individuals and are increasingly causes of morbidity and mortality. The pathogenesis of HIV-associated lung diseases and accelerated senescence of the lungs, which appear to be closely connected, are not well understood. As a result of these gaps in understanding, the ability to predict risk, provide accurate prognosis and develop effective preventive or treatment therapies is lacking.
The National Heart, Lung, and Blood Institute (NHLBI) funded eight clinical and basic research sites and one data coordinating center to form the overall network: